Belpointe Asset Management LLC Purchases New Shares in Exelixis, Inc. $EXEL

Belpointe Asset Management LLC purchased a new stake in Exelixis, Inc. (NASDAQ:EXEL) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 15,487 shares of the biotechnology company’s stock, valued at approximately $572,000.

A number of other hedge funds have also recently modified their holdings of EXEL. Frank Rimerman Advisors LLC raised its position in shares of Exelixis by 4.7% in the 1st quarter. Frank Rimerman Advisors LLC now owns 6,342 shares of the biotechnology company’s stock worth $234,000 after purchasing an additional 285 shares during the last quarter. Farther Finance Advisors LLC raised its position in Exelixis by 6.1% in the 1st quarter. Farther Finance Advisors LLC now owns 5,372 shares of the biotechnology company’s stock worth $195,000 after buying an additional 307 shares during the last quarter. Rathbones Group PLC raised its position in Exelixis by 5.3% in the 1st quarter. Rathbones Group PLC now owns 6,847 shares of the biotechnology company’s stock worth $253,000 after buying an additional 347 shares during the last quarter. Larson Financial Group LLC raised its position in Exelixis by 9.2% in the 1st quarter. Larson Financial Group LLC now owns 4,367 shares of the biotechnology company’s stock worth $161,000 after buying an additional 367 shares during the last quarter. Finally, Smartleaf Asset Management LLC raised its position in Exelixis by 14.8% in the 1st quarter. Smartleaf Asset Management LLC now owns 3,378 shares of the biotechnology company’s stock worth $124,000 after buying an additional 436 shares during the last quarter. Institutional investors own 85.27% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on EXEL shares. Stifel Nicolaus boosted their target price on Exelixis from $38.00 to $41.00 and gave the stock a “hold” rating in a research report on Tuesday, July 29th. Jefferies Financial Group set a $50.00 target price on Exelixis and gave the stock a “buy” rating in a research report on Tuesday, June 24th. Zacks Research lowered Exelixis from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 26th. Guggenheim reissued a “buy” rating and issued a $45.00 target price on shares of Exelixis in a research report on Tuesday, July 29th. Finally, UBS Group set a $38.00 price target on shares of Exelixis and gave the company a “neutral” rating in a research report on Wednesday, July 30th. Thirteen investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Exelixis presently has an average rating of “Moderate Buy” and an average price target of $44.06.

Exelixis Stock Up 0.2%

NASDAQ EXEL opened at $39.15 on Friday. The company has a 50-day moving average price of $39.97 and a 200-day moving average price of $39.64. The firm has a market capitalization of $10.54 billion, a P/E ratio of 18.82, a PEG ratio of 0.81 and a beta of 0.32. Exelixis, Inc. has a 52 week low of $25.17 and a 52 week high of $49.62.

Exelixis (NASDAQ:EXEL) last released its earnings results on Monday, July 28th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.63 by $0.12. The company had revenue of $568.26 million during the quarter, compared to analyst estimates of $574.36 million. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. The firm’s quarterly revenue was down 10.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.84 EPS. Exelixis has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Exelixis, Inc. will post 2.04 EPS for the current year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.